IL-2–inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells
Journal of Clinical Investigation · 17.02.2025 · 135 (4)
DOI: 10.1172/jci178558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 26.11.2024. Verfasst von Zheng Fu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Protein-Tyrosine Kinases, Interleukin-2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Despite the revolutionary achievements of chimeric antigen receptor (CAR) T cell therapy in treating cancers, especially leukemia, several key challenges still limit its therapeutic efficacy. Of particular relevance is the relapse of cancer in large part as a result of exhaustion and short persistence of CAR-T cells in vivo. IL-2–inducible T cell kinase (ITK) is a critical modulator of the strength of T cell receptor signaling, while its role in CAR signaling is unknown. By electroporation of CRISPR-associated protein 9 (Cas9) ribonucleoprotein (RNP) complex into CAR-T cells, we successfully deleted ITK in CD19-CAR-T cells with high efficiency. Bulk and single-cell RNA sequencing analyses revealed downregulation of exhaustion and upregulation of memory gene signatures in ITK-deficient CD19-CAR-T cells. Our results further demonstrated a significant reduction of T cell exhaustion and enhancement of T cell memory, with significant improvement of CAR-T cell expansion and persistence both in vitro and in vivo. Moreover, ITK-deficient CD19-CAR-T cells showed better control of tumor relapse. Our work provides a promising strategy of targeting ITK to develop sustainable CAR-T cell products for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Hubei Jiangxia Laboratory, Wuhan, Hubei, China.
- MegaRobo Technologies Co. Ltd., Suzhou, China.
- Xinyi Biotech Co. Ltd., Lingang, Shanghai, China.
- Institute of Hematology, Central South University, Changsha, Hunan, China.
- Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, China.
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
Zitieren
APA
Fu, Z., Huang, Z., Xu, H., Liu, Q., Li, J., Song, K., Deng, Y., Tao, Y., Zhang, H., Wang, P., Li, H., Sheng, Y., Zhou, A., Han, L., Fu, Y., Wang, C., Choudhary, S. K., Ye, K., Veggiani, G., …, & Peng, H. (2025). IL-2–inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells. Journal of Clinical Investigation, 135(4). https://doi.org/10.1172/jci178558
Vancouver
Fu Z, Huang Z, Xu H, Liu Q, Li J, Song K, et al. IL-2–inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells. Journal of Clinical Investigation. 2025;135(4). doi:10.1172/jci178558
BibTeX
@article{Fu2025,
author = {Fu, Zheng and Huang, Zineng and Xu, Hao and Liu, Qingbai and Li, Jing and Song, Keqing and Deng, Yating and Tao, Yujia and Zhang, Huifang and Wang, Peilong and Li, Heng and Sheng, Yue and Zhou, Aijun and Han, Lianbin and Fu, Yan and Wang, Chenzhi and Choudhary, Saurav Kumar and Ye, Kaixiong and Veggiani, Gianluca and Li, Zhihong and August, Avery and Huang, Weishan and Shan, Qiang and Peng, Hongling},
title = {IL-2–inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {4},
doi = {10.1172/jci178558}
}
EUVIMED